Medtronic Acquires SPR Therapeutics for Peripheral Nerve Stimulation System
Key Questions
What did Medtronic acquire and for how much?
Medtronic completed its $650 million acquisition of SPR Therapeutics, a pain management company. The deal includes SPR's Sprint PNS System, a minimally invasive peripheral nerve stimulation therapy.
What conditions does the Sprint PNS System treat?
The Sprint PNS System provides a temporary 60-day peripheral nerve stimulation therapy for chronic pain, including sciatica. It offers a non-permanent implant option in neuromodulation.
Why is Medtronic's acquisition of SPR Therapeutics significant?
The deal highlights growing industry investment in peripheral nerve stimulation therapies. It represents a key development in neuromodulation for treating chronic pain conditions like sciatica.
Medtronic closed a $650M acquisition of SPR Therapeutics and its Sprint PNS System, a minimally invasive 60-day peripheral nerve stimulation therapy for chronic pain, including sciatica. This is a significant development in neuromodulation, offering a temporary, non-permanent implant option. The acquisition signals growing industry investment in PNS for conditions like sciatica.